OMS 721

Drug Profile

OMS 721

Alternative Names: anti-MASP-2 monoclonal antibody; MASP-2 therapeutic; OMS-721

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator Omeros Corporation
  • Class Anti-inflammatories; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action MASP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic microangiopathies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome
  • Phase II Glomerulonephritis; IgA nephropathy; Lupus nephritis; Membranous glomerulonephritis; Thrombotic microangiopathies
  • Preclinical Stroke; Wet age-related macular degeneration

Most Recent Events

  • 13 Jun 2017 OMS 721 receives Breakthrough Therapy status for IgA nephropathy in USA
  • 17 May 2017 Interim efficacy data from phase II trial in Glomerulonephritis released by Omeros Corporation
  • 11 May 2017 Omeros Corporation files for Breakthrough therapy designation of OMS 721 with the FDA for treatment of patients with IgA nephropathy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top